Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
NCT07232719 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Retatrutide
Study Locations (20)
Texas
- Cedar Health Research — Dallas
- Headlands Research-El Paso — El Paso
- Cedar Health Research - Euless — Euless
- Cedar Health Research - Fort Worth — Fort Worth
- Care Access - Houston — Houston
- IMA Clinical Research San Antonio — San Antonio
Florida
- JEM Research Institute — Atlantis
- Headlands Research Orlando — Orlando
- Care Access - Tamarac — Tamarac
Missouri
- Clinical Research Professionals — Chesterfield
- Clinvest Headlands Llc — Springfield
California
- Artemis Institute for Clinical Research — Riverside
Illinois
- Care Access - Arlington Heights — Arlington Heights
Kentucky
- L-MARC Research Center — Louisville
Louisiana
- IMA Clinical Research Monroe - Armand — Monroe
Maryland
- Pharmasite Research, Inc. — Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-11-17 |
| Est. Completion | 2027-07 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07232719
The ClinicalTrials.gov registry entry for NCT07232719 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 704 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07232719 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Texas, Florida, Missouri. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07232719 about?
NCT07232719 is a clinical study titled "A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight". The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
What is the current status of trial NCT07232719?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2025-11-17. Estimated completion is 2027-07.
What conditions does trial NCT07232719 study?
This clinical trial studies the following conditions: Obesity, Overweight. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07232719?
The interventions under investigation include: Placebo (DRUG), Retatrutide (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07232719?
This trial is sponsored by Eli Lilly and Company, which has 704 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07232719 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.